Literature DB >> 21219314

Prophylactic, prandial rofecoxib treatment lacks efficacy against acute PTZ-induced seizure generation and kindling acquisition.

Robert J Claycomb1, Sandra J Hewett, James A Hewett.   

Abstract

PURPOSE: The goal of this study was to determine whether prophylactic prandial administration of rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, could alter seizure generation, kindling acquisition, and/or kindling maintenance in the mouse pentylenetetrazole (PTZ) epilepsy model.
METHODS: Male CD-1 mice were fed ad libitum with control chow or chow formulated to deliver 30 mg/kg/day rofecoxib. After 5 days, mice were treated with a single dose of 40 or 55 mg/kg PTZ (acute paradigm) or 40 mg/kg PTZ delivered daily (kindling paradigm). Seizure severity was scored on a four-point behavioral scale and COX-2 expression was assessed in brain slices from a subset of mice 3 h or 72 h after acute PTZ or following establishment of kindling. KEY
FINDINGS: Hippocampal COX-2 expression was transiently upregulated 3 h after an acute PTZ-induced convulsion and returned to baseline levels within 72 h, whereas it remained elevated for at least 72 h after the final seizure in the kindling paradigm. Despite this increase, chronic rofecoxib treatment did not attenuate the severity of acute PTZ-induced seizures and failed to alter kindling development or maintenance. SIGNIFICANCE: The present study demonstrates that prophylactic, prandial rofecoxib treatment lacks efficacy against acute PTZ-induced seizure generation and kindling acquisition, and does not reverse the kindled state once established. Wiley Periodicals, Inc.
© 2011 International League Against Epilepsy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21219314      PMCID: PMC4445939          DOI: 10.1111/j.1528-1167.2010.02889.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  51 in total

Review 1.  Cyclooxygenases: structural, cellular, and molecular biology.

Authors:  W L Smith; D L DeWitt; R M Garavito
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

2.  The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.

Authors:  R A Halpin; L A Geer; K E Zhang; T M Marks; D C Dean; A N Jones; D Melillo; G Doss; K P Vyas
Journal:  Drug Metab Dispos       Date:  2000-10       Impact factor: 3.922

3.  Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture.

Authors:  S J Hewett; T F Uliasz; A S Vidwans; J A Hewett
Journal:  J Pharmacol Exp Ther       Date:  2000-05       Impact factor: 4.030

4.  Characterization of inducible cyclooxygenase in rat brain.

Authors:  C D Breder; D Dewitt; R P Kraig
Journal:  J Comp Neurol       Date:  1995-05-01       Impact factor: 3.215

5.  Mapping loci for pentylenetetrazol-induced seizure susceptibility in mice.

Authors:  T N Ferraro; G T Golden; G G Smith; P St Jean; N J Schork; N Mulholland; C Ballas; J Schill; R J Buono; W H Berrettini
Journal:  J Neurosci       Date:  1999-08-15       Impact factor: 6.167

6.  Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor potentiates the anticonvulsant activity of tiagabine against pentylenetetrazol-induced convulsions in mice.

Authors:  A Dhir; S K Kulkarni
Journal:  Inflammopharmacology       Date:  2006-12       Impact factor: 4.473

7.  Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.

Authors:  C C Chan; S Boyce; C Brideau; S Charleson; W Cromlish; D Ethier; J Evans; A W Ford-Hutchinson; M J Forrest; J Y Gauthier; R Gordon; M Gresser; J Guay; S Kargman; B Kennedy; Y Leblanc; S Leger; J Mancini; G P O'Neill; M Ouellet; D Patrick; M D Percival; H Perrier; P Prasit; I Rodger
Journal:  J Pharmacol Exp Ther       Date:  1999-08       Impact factor: 4.030

8.  Inhibition of prostaglandin synthesis up-regulates cyclooxygenase-2 induced by lipopolysaccharide and peroxisomal proliferators.

Authors:  N A Callejas; A Castrillo; L Boscá; P Martín-Sanz
Journal:  J Pharmacol Exp Ther       Date:  1999-03       Impact factor: 4.030

9.  Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia.

Authors:  Eduardo Candelario-Jalil; Armando González-Falcón; Michel García-Cabrera; Dalia Alvarez; Said Al-Dalain; Gregorio Martínez; Olga Sonia León; Joe E Springer
Journal:  J Neurochem       Date:  2003-08       Impact factor: 5.372

10.  COX-2, but not COX-1, activity is necessary for the induction of perforant path long-term potentiation and spatial learning in vivo.

Authors:  T R Cowley; B Fahey; S M O'Mara
Journal:  Eur J Neurosci       Date:  2008-06-06       Impact factor: 3.386

View more
  16 in total

Review 1.  Cyclooxygenase-2 in epilepsy.

Authors:  Asheebo Rojas; Jianxiong Jiang; Thota Ganesh; Myung-Soon Yang; Nadia Lelutiu; Paoula Gueorguieva; Raymond Dingledine
Journal:  Epilepsia       Date:  2013-11-08       Impact factor: 5.864

2.  Celecoxib Ameliorates Seizure Susceptibility in Autosomal Dominant Lateral Temporal Epilepsy.

Authors:  Lin Zhou; Liang Zhou; Li-da Su; Sheng-Long Cao; Ya-Jun Xie; Na Wang; Chong-Yu Shao; Ya-Nan Wang; Jia-Huan Zhou; John K Cowell; Ying Shen
Journal:  J Neurosci       Date:  2018-02-28       Impact factor: 6.167

3.  Mice deficient in L-12/15 lipoxygenase show increased vulnerability to 3-nitropropionic acid neurotoxicity.

Authors:  Yan He; Rita C Akumuo; Yuan Yang; Sandra J Hewett
Journal:  Neurosci Lett       Date:  2017-02-14       Impact factor: 3.046

4.  P2X7-dependent constitutive Interleukin-1β release from pyramidal neurons of the normal mouse hippocampus: Evidence for a role in maintenance of the innate seizure threshold.

Authors:  Spandita S Dutta; Antoaneta A Andonova; Torsten Wöellert; Sandra J Hewett; James A Hewett
Journal:  Neurobiol Dis       Date:  2022-03-11       Impact factor: 5.996

5.  Sexually dimorphic and brain region-specific transporter adaptations in system xc- null mice.

Authors:  Heather M Sosnoski; Sheila M S Sears; Yan He; Carla Frare; Sandra J Hewett
Journal:  Neurochem Int       Date:  2020-10-22       Impact factor: 3.921

6.  Differential seizure response in two models of cortical heterotopia.

Authors:  Lisa A Gabel; Monica Manglani; Natalia Ibanez; Jessica Roberts; Raddy L Ramos; Glenn D Rosen
Journal:  Brain Res       Date:  2012-11-29       Impact factor: 3.252

Review 7.  Causes of CNS inflammation and potential targets for anticonvulsants.

Authors:  Mercé Falip; Xavier Salas-Puig; Carlos Cara
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

8.  Maintenance of the Innate Seizure Threshold by Cyclooxygenase-2 is Not Influenced by the Translational Silencer, T-cell Intracellular Antigen-1.

Authors:  Yifan Gong; James A Hewett
Journal:  Neuroscience       Date:  2018-01-11       Impact factor: 3.590

9.  Homostachydrine is a Xenobiotic Substrate of OCTN1/SLC22A4 and Potentially Sensitizes Pentylenetetrazole-Induced Seizures in Mice.

Authors:  Misa Nishiyama; Noritaka Nakamichi; Tomoyuki Yoshimura; Yusuke Masuo; Tomoe Komori; Takahiro Ishimoto; Jun-Ichi Matsuo; Yukio Kato
Journal:  Neurochem Res       Date:  2020-08-26       Impact factor: 3.996

10.  Inhibition of Death-associated Protein Kinase 1 protects against Epileptic Seizures in mice.

Authors:  Chen-Ling Gan; Yulian Zou; Yongfang Xia; Tao Zhang; Dongmei Chen; Guihua Lan; Yingxue Mei; Long Wang; Xindong Shui; Li Hu; Hekun Liu; Tae Ho Lee
Journal:  Int J Biol Sci       Date:  2021-06-11       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.